News|Articles|July 30, 2026

The Intelligence Economy: Human-Guided AI for Pharma's Next Era

As LiveWorld marks its 30th anniversary and introduces LiveInsight AI™, Chairman and CEO Peter Friedman discusses why human-led, AI-powered intelligence systems are essential for pharma organizations navigating hallucination risk and regulatory scrutiny. He explains how pairing curated data, tailored AI, and human expertise turns raw information into decision-grade insight. Friedman also outlines what will separate pharma organizations that thrive in this new "intelligence economy" from those that fall behind.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Related to this article

September 29th, 2026

Pharmaceutical Executive Daily: Fabrice Chouraqui Steps Down as CEO of Pharming

New U.S. guidance carves out tariff exemptions for specialty pharmaceuticals, Pharming's Fabrice Chouraqui steps down as CEO amid a board rift, and a dealmaking roundup covers Hengrui Pharma's licensing agreement with Novo Nordisk and AstraZeneca's investment in Summit Therapeutics.

September 29th, 2026

New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report

New U.S. guidance exempts orphan drugs, nuclear medicines, cell and gene therapies, and other specialty products from the 100% pharmaceutical tariff when imported from 19 named countries.

September 29th, 2026

Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board

Pharming CEO Fabrice Chouraqui has stepped down amid strategic disagreements with the board, with chief commercial officer Leverne Marsh and chief financial officer Kenneth Lynard now serving as interim co-CEOs.

September 29th, 2026

Roundup: Hengrui Pharma and Novo Enter Exclusive License Agreement for HRS-1596, AstraZeneca Enters Collaboartion with Summit Therapeutics

Novo licensed Hengrui's once-weekly oral GLP-1/GIP dual agonist HRS-1596 in a deal worth up to $2.6 billion, while AstraZeneca invested $2 billion in Summit Therapeutics to pair ivonescimab with its antibody-drug conjugate portfolio.

September 29th, 2026

The Evidence Gaps Digital Health Platforms Still Need to Close

Numerof's Michael Abrams on why digital health's cost-savings claims often don't hold up to scrutiny — and why the evidence gap matters.

September 29th, 2026

As Peptide Rulemaking Stalls, FDA Enforcement Moves Forward

While the FDA weighs a narrow, regulated path for compounded peptides, its enforcement arm is already taking action.

September 28th, 2026

Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal

Merck licenses a preclinical KRAS G12D inhibitor from SciBrunch, FDA approves Olumiant, Juvmo, and Atebrioz across three separate indications, and Matthew Montes de Oca makes the case for compounding pharmacies to set their own safety standards.

September 28th, 2026

Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch

Merck has acquired exclusive global rights to SciBrunch's preclinical KRAS G12D inhibitor SPR2015.

The Intelligence Economy: Human-Guided AI for Pharma's Next Era

Related to this article

Trending on PharmExec

Merck Licenses Preclinical KRAS G12D Inhibitor from SciBrunch

New U.S. Guidance Lays Out Exemptions for 100% Tariffs: Report

Pharming CEO Fabrice Chouraqui Steps Down Amid Strategic Disagreement with Board

Roundup: FDA Approves Lilly’s Olumiant, AbbVie’s Juvmo, Mirum & Incyte’s Atebrioz

Pharmaceutical Executive Daily: Merck Acquires SPR2015 in $2.13 Billion Licensing Deal